MP-2.236 General Approach to Genetic Testing · 2015. 5. 13. · MEDICAL POLICY POLICY TITLE...
Transcript of MP-2.236 General Approach to Genetic Testing · 2015. 5. 13. · MEDICAL POLICY POLICY TITLE...
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 1
Original Issue Date (Created): March 25, 2014
Most Recent Review Date (Revised): March 25, 2014
Effective Date: August 1, 2014
I. POLICY
This policy applies only if there is not a separate Medical Policy that outlines specific
criteria for testing. If a separate policy does exist, then the criteria for medical necessity in
that policy supersede the guidelines in this policy.
Genetic testing classified in one of the categories below may be considered medically
necessary when all criteria are met for each category.
Medical criteria
Genetic testing is considered medically necessary for a genetic or heritable disorder when the
following are met:
1. Diagnostic testing for genetic or heritable mutations of an affected individual
an association of the marker with the disorder has been established AND
symptoms of the disease are present AND
a definitive diagnosis cannot be made based upon history, physical
examination, pedigree analysis, standard diagnostic studies/tests AND
the clinical utility of a diagnosis has been established, (see Appendix) for
example by demonstrating that a definitive diagnosis will lead to changes in
clinical management of the condition, changes in surveillance or changes in
reproductive decision making, and the changes will lead to improved health
outcomes AND
establishing the diagnosis by genetic testing will end the clinical work-up for
other disorders
POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND
RATIONALE DEFINITIONS BENEFIT VARIATIONS
DISCLAIMER CODING INFORMATION REFERENCES
POLICY HISTORY
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 2
2. Risk assessment
a. Predictive and presymptomatic:
an association of the marker with future disorder has been established AND
the clinical utility has been established (see Appendix), for example by
demonstrating that testing will lead to improved health outcomes based on
prevention or early detection strategies
b. Carrier testing
an association of the marker with the disorder has been established AND
the genetic disorder is associated with a potentially severe disability or has a lethal natural history AND
the clinical utility has been established (see Appendix), for example by demonstrating that the results of the test will have an impact on family planning
3. Prognostic testing
an association of the marker with the natural history of the disease has been
established AND
the clinical utility of identifying the mutation has been established, for example
by demonstrating that it will lead to changes in clinical management of the
condition or changes in surveillance
4. Genetic variants that alter response to treatment or to an environmental factor
a. Constitutional (germline) testing:
the association of the marker with a phenotype/metabolic state that relates to drug efficacy or adverse drug reactions has been established AND
the clinical utility has been established (see Appendix), for example by demonstrating that the results of the genetic test will impact clinical decision
making and will be expected to result in improved clinical outcomes for the patient
based upon drug selection or dosage
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 3
b. Tissue-specific or tumor testing:
the association of a mutation with response to a particular drug has been
established AND
the clinical utility has been established (see Appendix), for example by
demonstrating that the patient is a candidate for targeted drug therapy which
is associated with a specific mutation
Genetic testing that does not meet the criteria for a specific category is considered
investigational or not medically necessary, according to the standard definitions used for these
terms (see Policy Guidelines).
Other Testing
“At-home” or “direct-to-consumer” genetic testing
“At-home” or “direct-to-consumer” genetic testing is considered investigational as there is
insufficient evidence to support a conclusion concerning the health outcomes or benefits associated
with this procedure.
Frequency of testing
In the absence of specific information regarding advances in the knowledge of mutation
characteristics for a particular disorder, the current literature indicates that genetic tests for inherited
disease need only be performed once per lifetime of the patient.
Policy Guidelines
Genetic testing is considered investigational when there is insufficient evidence to determine
whether the technology improves health outcomes.
Genetic testing is considered not medically necessary when:
testing is not considered standard of care, such as the clinical diagnosis can be made without
the use of a genetic test
testing is not clinically appropriate for the patient’s condition, for example, when it would
not change diagnosis and/or management. Other situations where testing is not clinically
appropriate include, but are not limited to:
o testing is performed entirely for non-medical (e.g., social) reasons
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 4
o testing is not expected to provide a definitive diagnosis that would obviate the need
for further testing.
testing is performed primarily for the convenience of the patient, physician or other health
care provider.
testing would result in outcomes that are equivalent to outcomes using an alternative
strategy, and the genetic test is more costly.
Cross-reference: Also see Appendix 2 for additional policies related to genetic testing.
MP-2.323 General Approach to Evaluating the Utility of Genetic Panels
MP-7.009 Preimplantation Genetic Testing
MP- 2.242 Chromosomal Microarray (CMA) Analysis for the Genetic Evaluation of Patients
with Developmental Delay/Intellectual Disability or Autism Spectrum Disorder
MP-2.050 Diagnostic Testing and Risk Assessment for Alzheimer’s disease
MP-2.233 Genetic Testing for Congenital Long QT Syndrome
MP-2.304 Pervasive Developmental Disorders
II. PRODUCT VARIATIONS TOP [N] = No product variation, policy applies as stated
[Y] = Standard product coverage varies from application of this policy, see below
* Benefits are available for specialized diagnostic genetic testing when it is medically necessary
to diagnose and/or manage a patient’s medical condition. However, genetic screening is not
covered.
* The FEP program dictates that all drugs, devices or biological products approved by the U.S.
Food and Drug Administration (FDA) may not be considered investigational. Therefore, FDA-
approved drugs, devices or biological products may be assessed on the basis of medical
necessity.
** Refer to Centers for Medicare and Medicaid Services (CMS) National Coverage Determination
(NCD) 190.3, Cytogenetic Studies. Also see Novitas Solutions Local Coverage Determination
(LCD) L34796 Biomarkers for Oncology and L33640 Biomarkers Overview.
[N] Capital Cares 4 Kids [N] Indemnity
[N] PPO [N] SpecialCare
[N] HMO [N] POS
[Y] SeniorBlue HMO** [Y] FEP PPO*
[Y] SeniorBlue PPO**
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 5
III. DESCRIPTION/BACKGROUND TOP
There are numerous commercially available genetic tests, including those used to guide
intervention in symptomatic or asymptomatic individuals, to identify individuals at risk for
future disorders, to predict the prognosis of diagnosed disease and to predict treatment
response. This concept policy offers a framework for evaluating the utility of genetic tests, by
classifying the types of genetic tests into clinically relevant categories and developing criteria
that can be used for evaluating tests in each category.
Purpose The purpose of this policy is to provide assistance in evaluating the utility of genetic
tests. In providing a framework for evaluating genetic tests, this policy will not attempt to determine the clinical utility of genetic testing for specific disorders. Rather, it provides
guidelines that can be applied to a wide range of different tests.
This policy does not include cytogenetic testing (karyotyping), biochemical testing, or
molecular testing for infectious disease.
This policy does not address prenatal testing. Prenatal testing involves particular ethical
concerns that are not easily addressed via review of the scientific evidence.
Definitions
Genetic testing: Genetic testing involves the analysis of chromosomes, DNA
(deoxyribonucleic acid), RNA (ribonucleic acid), genes or gene products to detect inherited
(germline) or non-inherited (somatic) genetic variants related to disease or health.
Carrier testing: A carrier of a genetic disorder has one abnormal allele for a disorder. When
associated with an autosomal recessive or X-linked disorder, carriers of the causative mutation
are typically unaffected. When associated with an autosomal dominant disorder, the individual
has one normal and one mutated copy of the gene, and may be affected with the disorder, may
be unaffected but at high risk of developing the disease later in life, or the carrier may remain
unaffected because of the sex-limited nature of the disease.
Carrier testing may be offered to individuals: A) who have family members with a genetic
condition; B) who have family members who are identified carriers; and C) who are members
of ethnic or racial groups known to have a higher carrier rate for a particular condition.
Germline mutations: Mutations that are present in the DNA of every cell of the body, present
from the moment of conception. These include cells in the gonads (testes or ova) and could
therefore be passed on to offspring.
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 6
Somatic mutations: Variations that occur with the passage of time, and are restricted to a
specific cell or cells derived from it. If these variations are limited to cells that are not in the
gonads, these variations will not be passed on to offspring.
Pharmacogenomics: The study of how an individual’s genetic makeup affects the body’s
response to drugs.
IV. RATIONALE TOP
General principles of genetic tests
The test should be cleared or approved by the U.S. Food and Drug Administration (FDA), or
performed in a Clinical Laboratory Improvement Amendment (CLIA) -certified laboratory.
Peer-reviewed literature on the performance and indications for the test should be available.
This evaluation of a genetic test focuses on 3 main principles: 1) analytic validity, which refers
to the technical accuracy of the test in detecting a mutation that is present or in excluding a
mutation that is absent; 2) clinical validity, which refers to the diagnostic performance of the
test (sensitivity, specificity, positive and negative predictive values) in detecting clinical disease;
and 3) clinical utility, i.e., how the results of the diagnostic test will be used to change
management of the patient and whether these changes in management lead to clinically
important improvements in health outcomes.
Types of genetic tests addressed in this policy
1. Diagnostic testing for genetic or heritable mutations in a symptomatic individual. This
refers to a molecular diagnosis defined by the presence of a known pathologic mutation.
For the purposes of genetic testing, a symptomatic individual is defined as an individual
with a clinical phenotype that is correlated with a known pathologic mutation.
2. Risk assessment for genetic and heritable mutations.
a. Predictive and presymptomatic types of testing are used to detect gene mutations associated with disorders that appear after birth, usually later in life. These tests can
be used in individuals with a family history of a genetic disorder, but who
themselves have no features of the disorder at the time of testing. Predictive testing
can identify mutations that increase an individual’s risk of developing disorders with
a genetic basis, such as certain types of cancer or cardiovascular disease.
Presymptomatic testing can determine whether a person will develop a genetic
disorder, before any signs or symptoms appear, by determining whether an
individual has a genetic mutation that may lead to development of the disease.
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 7
b. Carrier testing is performed in an individual who may be at risk of passing on a mutation to their children. This type of testing is offered to individuals who have a
family history of a genetic disorder and to people in certain ethnic groups with an
increased risk of specific genetic conditions.
3. Prognostic testing of diagnosed disease, to predict natural disease course, e.g., aggressiveness, recurrence, risk of death. This type of testing uses gene expression of
affected tissue to predict the course of disease, e.g., testing breast cancer tissue with
Oncotype DX
4. Genetic variants that alter response to treatment or to an environmental factor
a. Constitutional (germline) testing to detect genetic variants that alter risk of treatment response, adverse events, drug metabolism, drug effectiveness, etc., e.g.,
cytochrome p450 testing (also referred to as pharmacogenomics).
b. Tissue-specific or tumor testing: to detect mutations that predict response to a certain type of treatment (e.g., ALK mutation in non-small-cell lung cancer to
predict response to crizotinib)
c. Genetic mutations that adversely affect response to exposures in the environment that are ordinarily tolerated, such as G6PD deficiency, genetic disorders of immune
function, and aminoacidopathies.
Genetic counseling
The interpretation of the results of genetic tests and the understanding of risk factors can be very
difficult and complex. Therefore, most or all genetic testing for heritable conditions should be
preceded by genetic counseling so that the patient understands whether genetic testing should be
performed, or, if it is performed, what the potential impact of the information could be on the
patient and on his or her family.
Limitations of genetic testing
The testing methods may not detect all of the mutations that may occur in a gene
Genetic testing may identify variants of unknown clinical significance
Genetic testing may not necessarily determine the clinical outcome
Different genes can cause the same disease (genetic heterogeneity)
A mutation in a gene may cause different phenotypes (phenotypic heterogeneity)
Some disease-causing genes may not be identified as of yet
Genetic testing is subject to laboratory error
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 8
V. DEFINITIONS TOP
ANALYTIC VALIDITY of a genetic test defines its ability to accurately and reliably measure the
genotype of interest.
ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (also CMA, Chromosomal Microarray Analysis,
Microarray-based comparative genomic hybridization, array CGH, a-CGH, aCGH, or Virtual
Karyotype) is a technique to detect genomic copy number variations at a higher resolution level than
chromosome-based comparative genomic hybridization (CGH).
CHROMOSOME is one of the threadlike “packages” of genes and other DNA in the nucleus of a cell.
COPY-NUMBER VARIATIONS are alterations of the DNA of a genome that results in the cell having an
abnormal number of copies of one or more sections of the DNA. CNVs correspond to relatively large
regions of the genome that have been deleted (fewer than the normal number) or amplified (more than
the normal number) on certain chromosomes. For example, the chromosome that normally has
sections in order as A-B-C-D might instead have sections A-B-C-C-D (a duplication of "C") or A-B-D
(a deletion of "C").
CLINICAL VALIDITY of a genetic test defines its ability to detect or predict the associated disorder
(phenotype).
DIRECT-TO-CONSUMER GENETIC TESTING refers to genetic tests that are marketed directly to
consumers via television, print advertisements, or the Internet. This form of testing, which is also
known as at-home genetic testing, provides access to a person’s genetic information without
necessarily involving a doctor or insurance company in the process.
DNA a large nucleic acid molecule, found principally in the chromosomes of the nucleus of a cell,
that is the carrier of genetic information.
FIRST-DEGREE RELATIVE refers to a parent, sibling or child.
GENE is the basic unit of heredity, made of DNA, the code for a specific protein.
GENOTYPE is the specific genetic makeup of an individual, usually in the form of DNA.
KARYOTYPE is the chromosomal complement of an individual, including the number of
chromosomes and any abnormalities
MICROARRAY is a tool for analyzing gene expression that consists of a small membrane or glass slide containing samples of many genes arranged in a regular pattern. Each spot on an array is associated with a
particular gene. Each color in an array represents either healthy (control) or diseased (sample) tissue.
Depending on the type of array used, the location and intensity of a color will indicate whether the gene, or
mutation, is present in either the control and/or sample DNA. It will also provide an estimate of the
expression level of the gene(s) in the sample and control DNA.
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 9
MITOCHONDRIA are intracellular organelles that are responsible for energy production and cellular
respiration.
MITOCHONDRIAL DISEASE refers to one of hundreds of congenital illnesses that result from
mutations in mitochondrial DNA. As a result, the mitochondria are unable to completely burn food
and oxygen in order to generate energy.
MUTATION is a permanent structural alteration in DNA.
PHENOTYPE IS the physical characteristics of an organism or the presence of a disease that may or
may not be genetic.
RNA is a chemical similar to a single strand of DNA. RNA delivers DNA’s genetic message to the
cytoplasm of a cell where proteins are made.
SECOND-DEGREE RELATIVE refers to an aunt, uncle, niece, nephew, or grandparent.
SUBTELOMERIC is below the telomere, the end of a chromosome.
THIRD-DEGREE RELATIVE refers to a great aunt/uncle, first cousin or great grandmother/grandfather.
VARIABLE EXPRESSION REFERS to variation in the manner in which a trait is manifested. When
there is variable expressivity, the trait may vary in clinical expression from mild to severe.
VI. BENEFIT VARIATIONS TOP
The existence of this medical policy does not mean that this service is a covered benefit under
the member's contract. Benefit determinations should be based in all cases on the applicable
contract language. Medical policies do not constitute a description of benefits. A member’s
individual or group customer benefits govern which services are covered, which are excluded,
and which are subject to benefit limits and which require preauthorization. Members and
providers should consult the member’s benefit information or contact Capital for benefit
information.
VII. DISCLAIMER TOP
Capital’s medical policies are developed to assist in administering a member’s benefits, do not constitute medical
advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of
members. Members should discuss any medical policy related to their coverage or condition with their provider and
consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical
policy and a member’s benefit information, the benefit information will govern. Capital considers the information
contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 10
VIII. CODING INFORMATION TOP
Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms
of member benefit information. In addition, not all covered services are eligible for separate
reimbursement.
Covered when medically necessary:
Effective in 2013, if the specific analyte is listed in codes 81200-81355 or 81400-81408, that
CPT code would be reported. If the specific analyte is not listed in the more specific CPT
codes, unlisted code 81479 would be reported.
Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.
Diagnosis coding would depend on the condition for which the testing is being performed, if the
test is being performed as screening or carrier testing, and any family history of the condition.
*If applicable, please see Medicare LCD or NCD for additional covered diagnoses.
IX. REFERENCES TOP
1. Available online at: http://www.ncbi.nlm.nih.gov/sites/GeneTests/ Accessed November 6,
2013.
2. Available online at: http://www.nhmrc.gov.au/guidelines/publications/e99. Accessed
November 6, 2013.
3. Teutsch SM, Bradley LA, Palomaki GE et al. The evaluation of genomic applications in
practice and prevention (EGAPP) initiative: methods of the EGAPP Working Group.
Genet Med 2009; 11(1):3-14.
Other Sources
Novitas Solutions. Local Coverage Determination (LCD) L34796 Biomarkers for Oncology.
Effective 7/24/14. Assessed June 20, 2014.
Novitas Solutions. Local Coverage Determination (LCD) L33640 Biomarkers Overview.
Effective 12/5/13. Assessed June 25, 2014.
http://www.ncbi.nlm.nih.gov/sites/GeneTests/http://www.nhmrc.gov.au/guidelines/publications/e99http://www.novitas-solutions.com/webcenter/faces/oracle/webcenter/page/scopedMD/sad60252a_5537_4c5d_9350_ca405e36e159/Page128.jspx?wc.contextURL=%2Fspaces%2FMedicareJL&wc.originURL=%2Fspaces%2FMedicareJL%2Fpage%2Fpagebyid&contentId=00081277&_afrLoop=499336768241000#%40%3F_afrLoop%3D499336768241000%26wc.contextURL%3D%252Fspaces%252FMedicareJL%26wc.originURL%3D%252Fspaces%252FMedicareJL%252Fpage%252Fpagebyid%26contentId%3D00081277%26_adf.ctrl-state%3D104pm9zq50_61
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 11
Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) 190.3.
Cytogenetic Studies. Effective 7/16/1998. CMS [Website]: http://www.cms.hhs.gov.
Accessed June 25, 2014.
X. POLICY HISTORY TOP
MP- 2.326 CAC 5/24/14 New policy adopting BCBSA with additional CBC statements.
Guidelines provided for genetic testing when no specific policy is in place. MP
2.232 Genetic Testing for Inheritable Disease retired. The following statements
were extracted from that policy and placed in the new policy.
Information on at home or direct to consumer testing
Information regarding once per lifetime limit. Now silent on karyotyping (i.e. chromosome analysis)
APPENDIX 1 APPROACH TO DETERMINING CLINICAL UTILITY FOR GENETIC TESTING
Direct Evidence If direct evidence is available on the impact of testing on outcomes, this evidence takes precedence. Examples of direct evidence would be:
• Trial comparing outcomes with use of the test versus outcomes without use of the test • Associational study of genetic testing with outcomes
Indirect Evidence When direct evidence is not available, indirect evidence should be evaluated. Indirect evidence is evidence that addresses one or more components of a chain of evidence, but does not itself connect the intervention with the outcome. An example of indirect evidence is the accuracy of the genetic test for diagnosing the clinical condition, ie, clinical sensitivity and specificity. If improved accuracy leads to improved diagnosis of the disorder, and if more accurate diagnosis leads to management changes that improve outcomes, then clinical utility has been established. Many of these disorders are rare, and high-quality evidence on the efficacy of treatment for the disorder is often lacking. This is particularly true for aspects of management such as increased surveillance for complications, ancillary treatments (physical therapy, occupational therapy, etc.), and referrals to specialists. When evidence on outcomes is lacking, a consideration may be given as to whether these aspects of care are considered standard-of-care for that disorder, especially when they are part of guidelines by authoritative bodies.
http://www.cms.hhs.gov/
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 12
There are a number of factors that influence the strength of indirect evidence that is needed to determine whether health outcomes are improved. None of these factors are by themselves determinative of whether genetic testing should be performed, but they may be important determinants of the potential clinical utility of testing. Some of these considerations are as follows:
I. Factors impacting the strength of indirect evidence for diagnostic testing Disease Characteristics
Is life expectancy reduced with this disorder?
What is the level of physical and/or psychosocial morbidity (disability) associated with the disorder? o Severe morbidity/disability o Moderate morbidity/disability o Minor or no morbidity/disability
Impact of genetic test on diagnosis
Can genetic testing confirm the suspected diagnosis?
Can the diagnosis be confirmed by alternate methods without genetic testing?
o Disorder is defined by the presence of genetic mutation o Genetic test is one of several factors contributing to diagnosis o Unable to make diagnosis without genetic test in some patients
Can genetic testing rule out the disorder?
Can genetic testing eliminate the need for further clinical work-up?
o Is this a disorder in which the diagnosis can be difficult, and the patient may be subjected to long and complicated work-ups?
Impact of genetic test on management
Does confirmation of diagnosis by genetic testing lead to improved outcomes? o Initiation of effective treatment o Discontinue of ineffective treatment
Does confirmation of diagnosis by genetic testing lead to the Initiation of other management changes with uncertain impact on outcomes (referrals to specialists and/or ancillary care, initiate screening, etc.)
Does confirmation of diagnosis by genetic testing lead to initiation of other management changes that are considered “standard of care” treatment for disorder
Impact on Health Outcomes
Is there a definite improvement in health outcomes with genetic testing? o Eg, diagnosis cannot be made without genetic testing, and confirmation of diagnosis leads to
initiation of effective treatment
Is there a possible, but not definite, improvement in health outcomes with genetic testing?
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 13
o Eg.diagnosis cannot be made without genetic testing, and confirmation of diagnosis leads to
management changes with uncertain impact on outcomes
Are there significant barriers to research, such as rarity of the disorder?
What is the impact of genetic testing on lifestyle factors? o Employment/occupational decision-
making
o Leisure activities
o Reproductive decision-maker
Appendix Table A – Factors influencing the strength of an indirect chain of evidence on
clinical utility – diagnostic testing
Disorder Disease Characteristics
Impact on diagnosis
Impact on Management
Impact on outcomes
Sho
rten
ed L
E
Seve
re m
orb
idit
y/d
isab
ility
Mo
der
ate
mo
rbid
ity/
dis
abili
ty
Min
or
or
no
mo
rbid
ity/
dis
abili
ty
Co
nfi
rms
dia
gno
sis
Co
nd
itio
n
def
ined
by
mu
tati
on
Co
nfo
rms
dia
gno
sis,
o/w
Un
able
to m
ake
clin
ical
ly
Co
ntr
ibu
tes
to a
bili
ty t
o m
ake
dia
gno
sis
R
ule
s o
ut
dis
ord
er
Elim
inat
es n
eed
fo
r o
ther
clin
ical
wo
rku
p
In
itia
te e
ffec
tive
tre
atm
ent
for
dis
ord
er
D
isco
nti
nu
e in
effe
ctiv
e
trea
tmen
t
In
itia
te o
ther
man
agem
ent
chan
ges
P
rovi
de
‘sta
nd
ard
of
care
’
trea
tmen
t fo
r d
iso
rder
C
han
ge in
man
agem
ent
wit
h
imp
rove
d h
ealt
h o
utc
om
es
C
han
ge in
man
agem
ent
wit
h
un
cert
ain
imp
act
on
ou
tco
mes
Bar
rier
s to
res
earc
h
Imp
act
on
life
styl
e fa
cto
rs
II. Factors impacting the strength of indirect evidence for risk assessment testing Disease Characteristics
Is life expectancy reduced with this disorder?
What is the level of physical and/or psychosocial morbidity (disability) associated with the disorder? o Severe morbidity/disability o Moderate morbidity/disability
o Minor or no morbidity/disability
Is there a pre-symptomatic phase during which a clinical diagnosis cannot be made? Impact of genetic test on defining risk of disease
Can genetic testing determine the risk of subsequent disease in at least a substantial proportion of the population tested?
Is there a known mutation in the family?
Is the penetrance of the genetic mutation known?
Are there other factors that impact the clinical expression of disease?
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 14
Impact of genetic test on management
Does confirmation of risk lead to interventions that are indicated for this condition in the pre-symptomatic phase
o Interventions that prevent or delay disease onset
o Surveillance for manifestations or complications of disease
Does confirmation of risk by a positive genetic test lead to the initiation of other management changes that may or may not lead to improved outcomes (referrals to specialists and/or ancillary care, initiate screening, etc.)
Does a negative test confirm a lack of risk for the disease, and does this lead to “turning off” interventions, such as surveillance, that would otherwise be performed?
Is it likely that knowledge of mutation status will lead to alterations in reproductive decision-making?
Impact on Health Outcomes
Is there a definite improvement in health outcomes with genetic testing? o Eg, risk assessment cannot be made without genetic testing, and confirmation of risk leads to
initiation of effective preventive interventions that delay onset of disease
Is there a possible, but not definite, improvement in health outcomes with genetic testing?
o Eg risk assessment cannot be made without genetic testing, and confirmation of risk leads to
management changes with uncertain impact on outcomes
Are there significant barriers to research, such as rarity of the disorder?
What is the impact of genetic testing on lifestyle factors?
o Employment/occupational decision-making
o Leisure activities
o Reproductive decision-maker
Appendix Table 2 – Factors influencing the strength of evidence for risk assessment testing.
Disorder Disease Characteristics
Impact on defining risk
Impact on Management
Impact on outcomes
Sho
rten
ed L
E
Seve
re m
orb
idit
y/d
isab
ility
Mo
der
ate
mo
rbid
ity/
dis
abili
ty
M
ino
r o
r n
o m
orb
idit
y/d
isab
ility
Has
pre
-sym
pto
mat
ic s
tage
Det
erm
ines
ris
k in
su
bst
anti
al
pro
po
rtio
n o
f p
atie
nts
Kn
ow
n m
uta
tio
n in
fam
ily
Pen
etra
nce
is w
ell k
no
wn
Th
ere
are
oth
er
fact
ors
th
at
imp
act
clin
ical
exp
ress
ion
Elim
inat
es n
eed
fo
r o
ther
clin
ical
wo
rku
p
In
itia
te e
ffec
tive
inte
rve
nti
on
in
pre
-sym
pto
mat
ic p
has
e
O
ther
man
agem
ent
chan
ges
wit
h u
nce
rtai
n im
pac
t
N
egat
ive
test
tu
rns
off
inte
rve
nti
on
s
Like
ly t
o im
pac
t re
pro
du
ctiv
e
dec
isio
n-m
akin
g
D
efin
ite
imp
rove
d h
ealt
h
ou
tco
mes
P
oss
ible
imp
act
on
ou
tco
mes
,
'dat
a la
ckin
g
Bar
rier
s to
res
earc
h
Imp
act
on
life
styl
e fa
cto
rs
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 15
III. Factors influencing the strength of indirect evidence for prognosis testing
Disease Characteristics
• Is life expectancy reduced with this disorder? • What is the level of physical and/or psychosocial morbidity (disability) associated with the disorder?
o Severe morbidity/disability
o Moderate morbidity/disability
o Minor or no morbidity/disability
Impact of genetic test on prognosis
• Does the genetic test have an association with prognosis of disease? • Does genetic testing lead to an incremental improvement in prognosis above that which can be done
by usual testing?
• Does the genetic testing allow classification of patients into clinically credible prognostic groups? o Have these prognostic groups been defined clinically?
Impact of genetic test on management
• Are different prognostic groups associated with different treatment interventions?
o Type of intervention
o Timing of intervention
• Has treatment according to risk category been demonstrated to improve outcomes? • Is treatment according to risk category considered standard of care for this disorder?
Impact on Health Outcomes
• Is there a definite improvement in health outcomes with genetic testing? o Eg, Reclassification by prognosis leads to change in management that is known to be effective for the condition.
• Is there a possible, but not definite, improvement in health outcomes with genetic testing?
o Eg Reclassification by prognosis leads to changes in management with uncertain impact on outcomes
• Are there significant barriers to research, such as rarity of the disorder? • What is the impact of testing on lifestyle factors?
o Employment/occupational decision-making
o Leisure activities
o Reproductive decision-maker
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 16
Appendix Table 3 – Factors influencing the strength of indirect evidence - prognostic testing
Disorder Disease Characteristics
Impact on prognosis
Impact on Management
Impact on outcomes
Sho
rten
ed L
E
Seve
re m
orb
idit
y/d
isab
ility
Mo
der
ate
mo
rbid
ity/
dis
abili
ty
Min
or
or
no
mo
rbid
ity/
dis
abili
ty
Mu
tati
on
ass
oci
ate
d w
ith
pro
gno
sis
Incr
emen
tal i
mp
rove
men
t ab
ove
clin
ical
mea
sure
s
Co
ntr
ibu
tes
to a
bili
ty t
o m
ake
dia
gno
sis
Clin
ical
ly c
red
ible
pro
gno
stic
gro
up
s
Init
iate
eff
ecti
ve t
reat
men
t fo
r
dis
ord
er
D
isco
nti
nu
e in
effe
ctiv
e
Init
iate
oth
er m
anag
emen
t
chan
ges
P
rovi
de
‘sta
nd
ard
of
care
trea
tmen
t fo
r d
iso
rder
D
efin
ite
imp
rove
d h
ealt
h
ou
tco
mes
P
oss
ible
imp
act
on
ou
tco
mes
,
dat
a la
ckin
g
Bar
rier
s to
res
earc
h
Imp
act
on
life
styl
e fa
cto
rs
IV. Factors influencing the strength of indirect evidence for genetic variants that alter response to
treatment Disease Characteristics • Is life expectancy reduced with this disorder? • What is the level of physical and/or psychosocial morbidity (disability) associated with the disorder?
o Severe morbidity/disability
o Moderate morbidity/disability
o Minor or no morbidity/disability
• Is there effective pharmacologic therapy for this disorder? Impact of genetic testing on assessing response to treatment
• Can genetic testing define variants that are associated with different pharmacokinetics of drug metabolism?
• Are these changes in drug metabolism clinically important?
o Variants have been associated with clinically significant differences in outcomes of treatment
• Are there genetic variants that are associated with increased risk for adverse effects?
Impact of genetic test on pharmacologic management • Does identification of genetic variants lead to changes in pharmacologic management?
o Initiation of alternate agents
o Discontinue of ineffective agents
o Changes in dosing
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 17
Impact on Health Outcomes
• Is there a definite improvement in health outcomes with genetic testing?
o Eg, identification of variants leads to initiation of medications that are known to be effective.
• Is there a possible, but not definite, improvement in health outcomes with genetic testing?
o Eg identification of variants leads to change in pharmacologic management with uncertain impact
on outcomes
• Are there significant barriers to research, such as rarity of the disorder?
Appendix Table 3 – Factors influencing the strength of indirect evidence – genetic variants
that alter response to treatment Disorder Disease Characteristics
Impact on response to treatment
Impact on Management
Impact on outcomes
Sho
rten
ed L
E
Seve
re m
orb
idit
y/d
isab
ility
Mo
der
ate
mo
rbid
ity/
dis
abili
ty
M
ino
r o
r n
o m
orb
idit
y/d
isab
ility
Effe
ctiv
e p
har
mac
oki
net
ics
ph
arm
aco
logi
c th
erap
y
Def
ine
vari
ants
wit
h d
iffe
ren
t
ph
arm
aco
kin
etic
Dif
fere
nt
ph
arm
aco
kin
eti
cs a
re
clin
ical
ly im
po
rtan
t
Var
ian
ts le
ad t
o d
iffe
ren
ces
in
ou
tco
mes
Var
ian
ts w
ith
incr
ease
d r
isk
for
adve
rse
effe
cts
Init
iati
on
of
alte
rnat
e ag
en
ts
Dis
con
tin
ue
inef
fect
ive
trea
tmen
t
Ch
ange
s in
do
sin
g
Def
init
e im
pro
ved
hea
lth
ou
tco
mes
P
oss
ible
imp
act
on
ou
tco
mes
,
dat
a la
ckin
g
Bar
rier
s to
res
earc
h
Appendix 2: Policies related to genetic testing.
Please note: Due to the rapid changes taking place in the genetic testing field this may not
be a complete list of all the CBC genetic testing policies. Please review the CBC policy
website for additional policies which may have been added since the effective date of this
policy.
MP-2.235 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine
Prognosis in Patients with Breast Cancer
MP-2.242 Chromosomal Microarray (CMA) Analysis for the
Genetic Evaluation of Patients with Developmental Delay/Intellectual
Disability or Autism Spectrum Disorder
MP-2.234 Cytochrome p450 Genotyping
MP-2.050 Diagnostic Testing and Risk Assessment for Alzheimer’s Disease
(Biochemical and Genetic)
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 18
MP-2.244 DNA-Based Testing for Adolescent Idiopathic Scoliosis
MP-2.241 Epidermal Growth Factor Receptor (EGRF) Mutation Analysis for Patients
with Non-Small Cell Lung Cancer (NSCLC)
MP-7.006 First-Trimester Detection of Down Syndrome Using Fetal-Ultrasound
Markers Combined with Maternal Serum Assessment
MP-2.313 Gene Expression Testing to Predict Coronary Artery Disease
MP-2.323 General Approach to Evaluating the Utility of Genetic Panels
MP-2.251 Genetic Testing for Alpha-1 Antitrypsis Deficiency
MP-2.320 Genetic Testing for Alpha Thalassemia
MP-2.322 Genetic Testing for CHARGE Syndrome
MP-2.257 Genetic Testing for Duchenne and Becker Muscular Dystrophy
MP-2.321 Genetic Testing for Facioscpulohumeral Muscular Dystrophy
MP-2.246 Genetic Testing for Familial Cutaneous Malignant Melanoma
MP-2.308 Genetic Testing for Helicobacter Pylori Treatment
MP-2.312 Genetic Testing for Hereditary Hemochromatosis
MP-2.318 Genetic Testing for Hereditary Pancreatitis
MP-2.211 Genetic Testing for Inherited Breast and Ovarian Cancer
MP-2.253 Genetic Testing for Inherited Thrombophilia
MP-2.232 Genetic Testing for Inheritable Disease – to be retired 8/1/14
MP-2.310 Genetic Testing for Lipoprotein(a) Variant as a Decision Aid for Aspirin
Treatment
MP-2.233 Genetic Testing for Cardiac Ion Channelopathies (Formerly Genetic Testing
for Long QT Syndrome)
MP-5.013 Genetic Testing for Lynch Syndrome and Inherited Colon Cancer Syndromes
MP-2.319 Genetic Testing for Non-syndromic Hearing Loss
MP-2.248 Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy
MP-2.255 Genetic Testing for PTEN Hamartoma Tumor Syndrome
MP-2.307 Genetic Testing for Tamoxifen Treatment
MP-2.306 Genetic Testing for Warfarin Dose
MP-2.311 Genotyping for 9p21 Single Nucleotide Polymorphism
MP-9.002 Immune Cell Function Assay
MP-2.210 In Vitro Chemoreistance and Chemosensitivity Assays
MP-2.309 KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of
Statin Therapy
MP-2.240 KRAS Mutation Analysis in Non Small Cell Lung Cancer (NSCLC)
MP-2.316 KRAS and BRAF Mutation Analysis in Metastatic Colon Cancer
MP-2.245 Microarray-Based Gene Expression Test for Cancers of Unknown Primary
MP-2.231 Morphometric Based Testing
MP-2.252 Multianalyte Assays with Algorithmic Analysis for the Evaluation and
Monitoring of Patients with Chronic Liver Disease
MP-2.254 Multianalyte Assays with Algorithmic (MAAA) Interpretation for Predicting
Risk of Type 2 Diabetes
-
MEDICAL POLICY
POLICY TITLE GENERAL APPROACH TO GENETIC TESTING
POLICY NUMBER MP- 2.326
Page 19
MP-2.315 Multi-Gene Expression Assay for Predicting Colon Cancer Recurrence
MP- 2.249 Non-BRCA Breast Cancer Risk Assessment (OnceVue)
MP-2.247 NOTCH3 Genotyping for Diagnosis of CADASIL
MP-2.218 Pharmacogenomic and Metabolite Markers for Pts with Inflammatory Bowel
Disease Treated with Thiopurenes
MP-7.009 Preimplantation Genetic Testing
MP-2.256 Sequencing-Based Tests to Determine Trisomy 21 for Maternal Plasma DNA
MP-2.228 Serologic Diagnosis of Celiac Disease
MP-2.237 Systems Pathology for Predicting Risk of Recurrence in Prostate Cancer
MP-2.212 Tumor Markers and Tumor Related Molecular Testing
MP-2.250 Use of Common Genetic Variants to Predict Risk of Non-Familial Breast
Cancer
MP-2.324 Whole Exome Sequencing
Top
Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance
Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross
BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider
relations for all companies.